Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Shubham Pant, Alexander I. Spira, Byoung Chul Cho, Sanjay Goel, Christopher J. Hoimes, Ajjai Shivaram Alva, Rama Balaraman, Todd Michael Bauer, Philip A. Lowry, Ryan C. Ramaekers, Robert D. Siegel, Theresa Louise Werner, Nizar M. Tannir, Demiana Faltaos, Diane Potvin, Saskia T.C. Neuteboom, James Christensen, Richard C. Chao, Christos Kyriakopoulos
Institutions: The University of Texas MD Anderson Cancer Center, Virginia Cancer Specialists, Severance Hospital, Albert Einstein College of Medicine, Montefiore Medical Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, University of Michigan, Sarah Cannon, Tennessee Oncology, CHI Health St. Francis, Bon Secours Health System, University of Utah, Mirati Therapeutics (United States), University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890360625